BPH-652 treatment (0.5 mg twice per day (days 1, 0, 1, and 2), Intraperitoneal injection) significantly lowers S. aureusbacterial counts in the kidneys of the mice than those of the control group (P < 0.001), with 8 of 13 below the detection threshold, versus only 2 of 14 in the control group; on average, this result corresponds to a 98% decrease in surviving bacteria in the treatment group[1].
| Animal Model: | A systemic S. aureus infection model in mice[1]. |
| Dosage: | 0.5 mg twice per day (days 1, 0, 1, and 2). |
| Administration: | Intraperitoneal injection. |
| Result: | S. aureus bacterial counts in the kidneys of the mice treated with BPH-652 were significantly lower than those of the control group. |
